Cyclo Therapeutics Names Preeminent Neuroscientist and World-Renowned Researcher, Cynthia A. Lemere, PhD, as Senior Advisor for Advancement of Alzheimer’s Disease Asset
November 02 2021 - 8:05AM
Business Wire
– Dr. Lemere is a renowned translational
researcher focused on understanding, preventing, and treating
Alzheimer’s disease
– Company continues to advance evaluation of
Trappsol® Cyclo™ toward Phase 2 study in Alzheimer’s disease with
investigational new drug application (IND) filing on track before
year end
Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or
the “Company”), a clinical stage biotechnology company dedicated to
developing life-changing medicines through science and innovation
for patients and families living with diseases, today announced the
appointment of Cynthia A. Lemere, PhD as Senior Advisor for its
Alzheimer’s disease program.
Dr. Lemere is a distinguished scientist who currently serves in
the Ann Romney Center for Neurologic Diseases at Brigham and
Women's Hospital (BWH) and as Associate Professor of Neurology at
Harvard Medical School in Boston. She was a pioneer in the field of
using antibodies against amyloid-beta for the prevention or
treatment of Alzheimer's disease. Beginning in 1997, her research
laboratory has focused on the role of inflammation and the immune
system in the onset of Alzheimer's disease, paving the way for
identification of drug development targets to prevent or treat
Alzheimer’s disease. Her laboratory is funded by the National
Institutes of Health (NIH), NASA, and private foundations. Dr.
Lemere has served as a mentor to numerous doctoral and
post-doctoral students, helping to build the next generation of
leaders in Alzheimer’s Disease, and she is a highly sought-after
advisor to public sector and private groups.
“There remains significant unmet medical need in the treatment
of this devastating disease. As we continue to advance the
evaluation of Trappsol® Cyclo™ for the treatment of Alzheimer’s
disease, we are pleased to welcome Dr. Lemere to the team. Her
research and groundbreaking contributions to understanding and
using the immune system therapeutically to prevent and treat
Alzheimer’s disease is a valuable asset that we believe will
provide insightful perspective as we work to enter a Phase 2 study
in this disease and advance this critical program,” commented Lise
Lund Kjems, MD, PhD, Chief Medical Officer of Cyclo
Therapeutics.
“Dr. Lemere is a highly recognized and well-established Thought
Leader in Alzheimer’s disease research. Her leadership, expertise,
and passion are noteworthy additions to Cyclo Therapeutics, and
they are in-line with our own dedication to helping patients and
families suffering from this insidious disease. We continue to be
encouraged by the potential of Trappsol® Cyclo™ and look forward to
furthering its development for Alzheimer’s disease,” added Sharon
Hrynkow, PhD, Chief Scientific Officer, Senior Vice President of
Medical Affairs of Cyclo Therapeutics.
Dr. Lemere’s current research involves non-clinical studies of
antibody treatments targeting a pathogenic form of amyloid-beta
protein in Alzheimer’s disease; the role of complement signaling in
aging and Alzheimer’s disease; and the effects of deep space
galactic cosmic radiation on brain aging and the risk of
Alzheimer’s disease in studies in mouse models and human neural
cells in preparation for NASA’s first manned mission to Mars in the
2030s. She is a member and the past chair of the Alzheimer’s
Association’s Medical and Scientific Advisory Group and a former
member of the Association’s Board of Directors. She is also a
member of the Cure Alzheimer’s Fund Research Leadership Group. In
addition, she serves as a scientific advisor for several
foundations, conferences and companies.
“Physicians and families within the Alzheimer’s disease
community continue to be faced with significant unmet medical
needs. I believe the positive results that have been demonstrated
by Trappsol Cyclo/beta cyclodextrins to date in pre-clinical
studies and the Company’s compassionate use program are encouraging
and reaffirm furthering its development. I’m excited to join this
dedicated team to help advance the development of Trappsol Cyclo
for the treatment of Alzheimer’s disease as quickly and efficiently
as possible,” added Dr. Lemere.
Dr. Lemere earned a bachelor’s degree in psychology and
education from Mount Holyoke College and a master’s in neurobiology
from SUNY Albany. She then went on to examine Alzheimer's-related
brain changes in people with Down syndrome in the Selkoe Laboratory
at BWH while pursuing her doctorate in Pathology at Boston
University School of Medicine. After receiving her Ph.D., she
remained at the BWH Ann Romney Center for Neurologic Diseases
within the Department of Neurology where she is an associate
professor.
Cyclo Therapeutics is planning to evaluate Trappsol® Cyclo™, the
company’s proprietary formulation of hydroxypropyl beta
cyclodextrin, for the treatment of Alzheimer’s disease, targeting
the reduction of amyloid beta and tau. As part of a Type B
interaction with the FDA, Cyclo Therapeutics received positive
feedback supporting the Company’s development strategy to submit an
IND application for a Phase 2 study of intravenous Trappsol® Cyclo™
in the treatment of early Alzheimer’s disease. The Company is on
track to file its IND for a Phase 2 study of Alzheimer’s disease
before year-end 2021.
About Cyclo Therapeutics
Cyclo Therapeutics, Inc. is a clinical-stage biotechnology
company dedicated to developing life-changing medicines through
science and innovation for patients and families suffering from
disease. The Company’s Trappsol® Cyclo™, an orphan drug designated
product in the United States and Europe, is the subject of four
formal clinical trials for Niemann-Pick Disease Type C, a rare and
fatal genetic disease, (www.ClinicalTrials.gov NCT02939547,
NCT02912793, NCT03893071 and NCT04860960). The Company is planning
an early phase clinical trial using Trappsol® Cyclo™ intravenously
in Alzheimer’s Disease based on encouraging data from an Expanded
Access program for late-onset Alzheimer’s Disease (NCT03624842).
Additional indications for the active ingredient in Trappsol®
Cyclo™ are in development. For additional information, visit the
Company’s website: www.cyclotherapeutics.com.
Safe Harbor Statement
This press release contains “forward-looking statements” about
the company’s current expectations about future results,
performance, prospects and opportunities, including, without
limitation, statements regarding the satisfaction of closing
conditions relating to the offering and the anticipated use of
proceeds from the offering. Statements that are not historical
facts, such as “anticipates,” “believes” and “expects” or similar
expressions, are forward-looking statements. These statements are
subject to a number of risks, uncertainties and other factors that
could cause actual results in future periods to differ materially
from what is expressed in, or implied by, these statements. The
factors which may influence the company’s future performance
include the company’s ability to obtain additional capital to
expand operations as planned, success in achieving regulatory
approval for clinical protocols, enrollment of adequate numbers of
patients in clinical trials, unforeseen difficulties in showing
efficacy of the company’s biopharmaceutical products, success in
attracting additional customers and profitable contracts, and
regulatory risks associated with producing pharmaceutical grade and
food products. These and other risk factors are described from time
to time in the company’s filings with the Securities and Exchange
Commission, including, but not limited to, the company’s reports on
Forms 10-K and 10-Q. Unless required by law, the company assumes no
obligation to update or revise any forward-looking statements as a
result of new information or future events.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211102005730/en/
Investor Contact: JTC Team, LLC Jenene Thomas (833)
475-8247 CYTH@jtcir.com
Cyclo Therapeutics (NASDAQ:CYTH)
Historical Stock Chart
From Aug 2024 to Sep 2024
Cyclo Therapeutics (NASDAQ:CYTH)
Historical Stock Chart
From Sep 2023 to Sep 2024